You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

NABUMETONE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Nabumetone patents expire, and when can generic versions of Nabumetone launch?

Nabumetone is a drug marketed by Annora Pharma, Aurobindo Pharma Usa, Chartwell Molecules, Chartwell Rx, Copley Pharm, Epic Pharma Llc, Impax Labs Inc, Invagen Pharms, Lgm Pharma, Nostrum Labs Inc, Oxford Pharms, Sciegen Pharms Inc, and Watson Labs. and is included in thirteen NDAs.

The generic ingredient in NABUMETONE is nabumetone. There are twenty drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the nabumetone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nabumetone

A generic version of NABUMETONE was approved as nabumetone by CHARTWELL RX on February 25th, 2002.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NABUMETONE?
  • What are the global sales for NABUMETONE?
  • What is Average Wholesale Price for NABUMETONE?
Drug patent expirations by year for NABUMETONE
Drug Prices for NABUMETONE

See drug prices for NABUMETONE

Drug Sales Revenue Trends for NABUMETONE

See drug sales revenues for NABUMETONE

Recent Clinical Trials for NABUMETONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Fundação de Amparo à Pesquisa do Estado de São PauloPhase 4
Federal University of São PauloPhase 4
The Danish Rheumatism AssociationN/A

See all NABUMETONE clinical trials

Pharmacology for NABUMETONE

US Patents and Regulatory Information for NABUMETONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Annora Pharma NABUMETONE nabumetone TABLET;ORAL 090445-001 Jan 12, 2011 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lgm Pharma NABUMETONE nabumetone TABLET;ORAL 203166-002 Aug 30, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sciegen Pharms Inc NABUMETONE nabumetone TABLET;ORAL 078420-002 Sep 24, 2008 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chartwell Rx NABUMETONE nabumetone TABLET;ORAL 075280-001 Feb 25, 2002 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Aurobindo Pharma Usa NABUMETONE nabumetone TABLET;ORAL 090516-002 Jul 12, 2010 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Impax Labs Inc NABUMETONE nabumetone TABLET;ORAL 075189-001 May 26, 2000 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Nostrum Labs Inc NABUMETONE nabumetone TABLET;ORAL 090427-002 Dec 30, 2011 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.